Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

1.

Semagacestat, a gamma-secretase inhibitor for the potential treatment of Alzheimer's disease.

Imbimbo BP, Peretto I.

Curr Opin Investig Drugs. 2009 Jul;10(7):721-30.

PMID:
19579178
2.

Interacting with γ-secretase for treating Alzheimer's disease: from inhibition to modulation.

Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Logroscino G, Santamato A, Greco A, Seripa D, Pilotto A.

Curr Med Chem. 2011;18(35):5430-47. Review.

PMID:
22087836
3.

ACS chemical neuroscience molecule spotlight on semagacestat (LY450139).

Hopkins CR.

ACS Chem Neurosci. 2010 Aug 18;1(8):533-4. doi: 10.1021/cn1000606.

4.

Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.

D'Onofrio G, Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Paroni G, Cascavilla L, Seripa D, Pilotto A.

Expert Opin Drug Discov. 2012 Jan;7(1):19-37. doi: 10.1517/17460441.2012.645534. Epub 2011 Dec 14. Review.

PMID:
22468891
5.

What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease?

Cummings J.

Biol Psychiatry. 2010 Nov 15;68(10):876-8. doi: 10.1016/j.biopsych.2010.09.020. No abstract available.

PMID:
21035622
6.

γ-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes.

Imbimbo BP, Giardina GA.

Curr Top Med Chem. 2011;11(12):1555-70. Review.

PMID:
21510832
7.

A phase 3 trial of semagacestat for treatment of Alzheimer's disease.

Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG, Aisen PS; Alzheimer's Disease Cooperative Study Steering Committee, Siemers E, Sethuraman G, Mohs R; Semagacestat Study Group.

N Engl J Med. 2013 Jul 25;369(4):341-50. doi: 10.1056/NEJMoa1210951.

8.

What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us.

Schor NF.

Ann Neurol. 2011 Feb;69(2):237-9. doi: 10.1002/ana.22365.

PMID:
21387368
9.

Therapeutic potential of gamma-secretase inhibitors and modulators.

Imbimbo BP.

Curr Top Med Chem. 2008;8(1):54-61. Review.

PMID:
18220933
10.

Lessons from a failed γ-secretase Alzheimer trial.

De Strooper B.

Cell. 2014 Nov 6;159(4):721-6. doi: 10.1016/j.cell.2014.10.016.

11.

Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab.

Carlson C, Estergard W, Oh J, Suhy J, Jack CR Jr, Siemers E, Barakos J.

Alzheimers Dement. 2011 Jul;7(4):396-401. doi: 10.1016/j.jalz.2011.05.2353.

PMID:
21784350
12.

Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse.

Hyde LA, McHugh NA, Chen J, Zhang Q, Manfra D, Nomeir AA, Josien H, Bara T, Clader JW, Zhang L, Parker EM, Higgins GA.

J Pharmacol Exp Ther. 2006 Dec;319(3):1133-43. Epub 2006 Aug 31.

13.

Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings.

Henley DB, Sundell KL, Sethuraman G, Dowsett SA, May PC.

Curr Med Res Opin. 2014 Oct;30(10):2021-32. doi: 10.1185/03007995.2014.939167. Epub 2014 Jul 14.

PMID:
24983746
14.

Molecule of the month. Semagacestat.

[No authors listed]

Drug News Perspect. 2008 Sep;21(7):390. No abstract available.

PMID:
19259551
15.

Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease.

Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson A, Tariot P, Zoulnouni P, Galvin JE, Holtzman DM, Knopman DS, Satterwhite J, Gonzales C, Dean RA, May PC.

Neurology. 2006 Feb 28;66(4):602-4.

PMID:
16505324
16.

Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease.

Henley DB, May PC, Dean RA, Siemers ER.

Expert Opin Pharmacother. 2009 Jul;10(10):1657-64. doi: 10.1517/14656560903044982. Review.

PMID:
19527190
17.

Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment of Alzheimer's Disease.

Rosenberg PB, Lanctôt KL, Herrmann N, Mintzer JE, Porsteinsson AP, Sun X, Raman R.

J Alzheimers Dis. 2016 Aug 10;54(1):373-81. doi: 10.3233/JAD-151113.

PMID:
27567808
18.

Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs.

Portelius E, Van Broeck B, Andreasson U, Gustavsson MK, Mercken M, Zetterberg H, Borghys H, Blennow K.

J Alzheimers Dis. 2010;21(3):1005-12. doi: 10.3233/JAD-2010-100573.

PMID:
20634579
19.

Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.

Martone RL, Zhou H, Atchison K, Comery T, Xu JZ, Huang X, Gong X, Jin M, Kreft A, Harrison B, Mayer SC, Aschmies S, Gonzales C, Zaleska MM, Riddell DR, Wagner E, Lu P, Sun SC, Sonnenberg-Reines J, Oganesian A, Adkins K, Leach MW, Clarke DW, Huryn D, Abou-Gharbia M, Magolda R, Bard J, Frick G, Raje S, Forlow SB, Balliet C, Burczynski ME, Reinhart PH, Wan HI, Pangalos MN, Jacobsen JS.

J Pharmacol Exp Ther. 2009 Nov;331(2):598-608. doi: 10.1124/jpet.109.152975. Epub 2009 Aug 11.

20.

Secretase inhibitors and modulators for Alzheimer's disease treatment.

Tomita T.

Expert Rev Neurother. 2009 May;9(5):661-79. doi: 10.1586/ern.09.24. Review.

PMID:
19402777

Supplemental Content

Support Center